Dermatoscopic and clinical features of congenital or congenital-type nail matrix nevi: A multicenter prospective cohort study by the International Dermoscopy Society
Félix Pham(Hospices Civils de Lyon), L. Thomas(University of Liverpool), Je‐Ho Mun(Seoul National University), Thomas Schopf(University Hospital of North Norway), D. Moreno‐Ramírez(Hospital Universitario Virgen Macarena), D. Bessis(Université de Montpellier), Željko Mijušković(Military Medical Academy), Alice Phan(Hôpital Femme Mère Enfant), Mariame Meziane(Mohammed V University), C. Droitcourt(Centre Hospitalier Universitaire de Rennes), Linda K. Martin(The University of Sydney), Philippe Bahadoran, Josep Malvehy(Universitat de Barcelona), F. Skowron, Moon‐Bum Kim(Pusan National University), Aimilios Lallas(Aristotle University of Thessaloniki), Isabelle Tromme(Cliniques Universitaires Saint-Luc), Amélie Boespflug(Université Claude Bernard Lyon 1), Masaru Tanaka, Grażyna Kamińska‐Winciorek(The Maria Sklodowska-Curie National Research Institute of Oncology), P. Vabres(CHU Dijon Bourgogne), Pascale Guitera(The University of Sydney), Laura Weiler(Hospices Civils de Lyon), Alon Scope(Memorial Sloan Kettering Cancer Center), Dai Ogata(Unknown), X. Balguérie(Université de Rouen Normandie), Holger A. Haenssle(Heidelberg University), Giuseppe Argenziano(Regione Campania), Stéphane Dalle(Hospices Civils de Lyon), Nicolas Poulalhon(Hospices Civils de Lyon), Susana Puig(Instituto de Salud Carlos III), A.-C. Davaine(Centre Hospitalier des Pays de Morlaix), Iris Zalaudek(Azienda Sanitaria Universitaria Integrata di Trieste), J. Miquel(Peuplements végétaux et bioagresseurs en milieu tropical), Cloé Corven-Benoit, Ashfaq A. Marghoob(Memorial Sloan Kettering Cancer Center), Caroline Robert(Institut Gustave Roussy), J.F. BOURKE(South Infirmary Victoria University Hospital), Gérard Duru(Cythelia (France)), M. Marque(Centre Hospitalier Universitaire de Nîmes), C. Chiavérini(Centre Hospitalier Universitaire de Nice), Osvaldo Correia(Universidade do Porto), Cliff Rosendahl(The University of Queensland)
Cited by 24
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.8k